Prospective data show ustekinumab dosing influences outcomes in pediatric Crohn's disease, implying streamlined treatment strategies.
Children <40 kg required more IV ustekinumab (median 9 mg/kg; 250 mg/m²) to achieve similar week 8 levels as children ≥40kg receiving conventional adult 6 mg/kg weight-tiered induction. Higher week 8 levels were associated with favorable later outcomes.
No takes yet. Share an insight, caveat, or question.
Ricciuto et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: